| pembrolizumab based treatment |
| pembrolizumab alone | pembrolizumab plus 5FU plus platin |
mHNSCC - 1st line (L1) | | |
mHNSCC - L1 - all population 2 | | |
mHNSCC - L1 - PDL1 positive 4 | | |
Comparator:
vs cetuximab plus platin plus 5FU;
Risk of bias:
low;
some concerns;
high;
NA;